HYPERTENSION IN POSTMENOPAUSAL WOMEN: RATIONALE FOR THE USE OF CALCIUM CHANNEL BLOCKERS IN ANTIHYPERTENSIVE THERAPY
Abstract
The choice of antihypertensive drugs for the treatment of hypertensive patients is discussed. Modern recommendations on the use of antihyperten-sive drugs in various clinical situations (lesion of target organs and the presence of concomitant conditions) are presented. Characteristics of patients with hypertension and obesity in the postmenopausal period are presented with using authors own data. The expediency of using the last generation of calcium channel blockers in this clinical situation with an emphasis on lercanidipine is justified.
About the Authors
O. A. Kislyak
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Oksana A. Kislyak – MD, PhD, Professor, Head of Chair of Faculty Therapy, Medical Faculty
Ostrovitianova ul. 1, Moscow, 117997
A. V. Starodubova
Pirogov Russian National Research Medical University;
Federal Research Center for Nutrition, Biotechnology and Food Safety
Russian Federation
Russian Federation
Antonina V. Starodubova – MD, PhD, Professor, Chair of Faculty Therapy, Medical Faculty, Pirogov Russian National Research Medical University; Deputy Director, Federal Research Center for Nutrition, Biotechnology and Food Safety
Ustyinsky proezd 2/14, Moscow, 109240
A. A. Kopelev
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Alexander A. Kopelev – MD, PhD, Associate Professor, Chair of Faculty Therapy, Medical Faculty
Ostrovitianova ul. 1, Moscow, 117997
References
1. 2013 ESH/ESC Guidelines for the management of arterial hypertension. TheTask Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Journal of Hypertension. 2013;31:1281-357.
2. Diagnosis and treatment of hypertension. Russian recommendations (fourth revision). Sistemnye Gipertenzii. 2010; 3: 5-26. (In Russ.) [Диагностика и лечение артериальной гипертензии. Российские рекомендации (четвертый пересмотр). Системные Гипертензии. 2010;3:5-26].
3. Diagnosis and treatment of hypertension. Clinical Guidelines. Moscow: RMOAG; 2013. Available at: http://www.gipertonik.ru/files/recommendation/Recommendations_hypertension.docx. Checked by Jun 18, 2017. (In Russ.) [Диагностика и лечение артериальной гипертензии. Клинические рекомендации. Москва: РМОАГ; 2013. Доступно на: http://www.gipertonik.ru/files/recommendation/Recommendations_hypertension.docx. Проверено 18.06.2017].
4. Starodubova A.V., Kislyak O.A., Storozhakov G.I. Weight gain and obesity in women. Serdtse. 2005;5:254-9. (In Russ.) [Стародубова А.В., Кисляк О.А., Сторожаков Г.И. Прирост массы тела и ожирение у женщин. Сердце. 2005;5:254-9].
5. Kislyak O.A., Tsareva O.N., Starodubova A.V. Menopausal metabolic syndrome: experience with angiotensin receptor blocker treatment with telmisartan. Spravochnik Prakticheskogo Vracha. 2007;2:38-44. (In Russ.) [Кисляк О.А. , Царева О.Н., Стародубова А.В. Менопаузальный метаболический синдром: опыт лечения блокатором рецепторов ангиотензина телмисартаном. Справочник Практического Врача. 2007;2:38-44].
6. Kislyak O.A., Labutin A.V., Pokhilchenko M.V., Latyshev Т.V. The choice of combination therapy for the treatment of hypertension in high-risk patients. Lechebnoe Delo. 2012;1:29-34. (In Russ.) [Кисляк О.А., Лабутин А.В., Похильченко М.В., Латышев Т.В. Выбор комбинированной терапии для лечения артериальной гипертензии у пациентов высокого риска. Лечебное Дело. 2012;1:29-34].
7. Starodubova A.V., Chervyakova Yu.B., Kopelev A.A., Alieva A.M. Possibilities of pharmacological correction of metabolic disorders and prevention of diabetes mellitus in cases of disorders of carbohydrate metabolism. Lechebnoe Delo. 2015;3:59-66. (In Russ.) [Стародубова А.В., Ю.Б. Червякова Ю.Б., Копелев А.А., Алиева А.М. Возможности медикаментозной коррекции метаболических нарушений и профилактики сахарного диабета при нарушениях углеводного обмена. Лечебное Дело. 2015;3:59-66].
8. Frolova A.G. Reproductive health of a woman. Kachestvo zhizni. Meditsina. 2004;9:12. (In Russ.) [Фролова А.Г. Репродуктивное здоровье женщины. Качество жизни. Медицина. 2004;9:12].
9. Demidova T.Yu., Ametov AS, Parkhonina E.S. Obesity is the basis of metabolic syndrome. Lechashchiy Vrach. 2002;5:28-31. (In Russ.) [Демидова Т.Ю., Аметов А.С., Пархонина Е.С. Ожирение - основа метаболического синдрома. Лечащий Врач. 2002;5:28-31].
10. Naslund I. Lessons from the Swedish Obese Subjects Study: The effects of surgically induced weight loss on obesity comorbidity. Surg Obes Relat Dis. 2005;1:140-4.
11. Maslova N.P., Baranova E.I. Hypertensive disease in women. SPb.: SPbGMU; 2000. (In Russ.) [Маслова Н.П., Баранова Е.И. Гипертоническая болезнь у женщин. СПб.: издательство СПбГМУ; 2000].
12. Kislyak O.A., Starodubova A.V. The value of determining arterial stiffness and central pressure for assessing cardiovascular risk and the results of treatment of patients with hypertension. Consilium Medicum. 2009;11(10):42-7. (In Russ.) [Кисляк О.А., Стародубова А.В. Значение определения артериальной жесткости и центрального давления для оценки сердечно-сосудистого риска и результатов лечения пациентов с артериальной гипертензией. Consilium Medicum. 2009;11(10):42-7]
13. Beckey C., Lundy A., Lutfi N. Lercanidipine in the treatment of Hypertension. The Annals of Pharma-cotherapy. 2007;41:465-73.
14. Omboni S., Zanchetti A. Antihypertensive efficacy of Lercanidipine at 2,5, 5, and 10 mg in mild to moderate essential hypertension assessed by clinic and ambulatory blood pressure measurements. J Hypertens. 1998;16:1831-8.
15. Romito R., Pansini M.I., Perticone F., et al. Comparative effect of lercandipine, felodipine and nifidipine GTIS on blood pressure and heart rate in patients with mild to moderate arterial hypertension: the Lercandipine in Adults (LEAD) Study. J Clin Hypertens (Greenwich). 2003;5(4):249-53.
16. Leonetti G., Magnani B., Pessina A.C., et al.; COHORT Study Group. Tolerability of long term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives. Hypertension. 2002;15(11):932-40.
17. Barchielli M., Dolfini E., Farina P., et al. Clinical pharmacokinetics of lercanidipine. J Cardiovasc Pharmacol. 1997;29(suppl 2):S1-S15.
18. Peixiao S., Ningyuan F., Haiya W. Lercanidipine effect on circulating CD34þ progenitor cells in elderly patients: a randomized study. Curr Med Res Opin. 2016;32(sup 2):9-12.
19. Umemura T., Higashi Y. Endothelial progenitor cells: therapeutic target for cardiovascular diseases. J Pharmacol Sci. 2008;108:1-6.
20. Boilson B.A., Kiernan T.J., Harbuzariu A., et al. Circulating CD34þ cell subsets in patients with coronary endothelial dysfunction. Nat Clin Pract Cardiovasc Med. 2008;5:489-96.
21. Herbette L.G., Vecchiarelli M., Leonardi A. Lercanidipine: Short plasma half-life, long duration of action. J Cardiovasc Pharmacol 1997;29(suppl 1):S19-S24.
22. Roblesa N.R., Calvo C., Sobrinoc J., et al. Lercanidipine valuable effect on urine protein losses: the RED LEVEL study. Curr Med Res Opin. 2016;32(sup 2):29-34.
Review
For citations:
Kislyak O.A., Starodubova A.V., Kopelev A.A. HYPERTENSION IN POSTMENOPAUSAL WOMEN: RATIONALE FOR THE USE OF CALCIUM CHANNEL BLOCKERS IN ANTIHYPERTENSIVE THERAPY. Rational Pharmacotherapy in Cardiology. 2017;13(3):391-397. (In Russ.) https://doi.org/10.20996/1819-6446-2017-13-3-391-397
Views: 727
Email this article 